Loading...
Loading...
NVAX| Name | Value |
|---|---|
| Revenues | 81.0M |
| Cost of Revenue | 34.1M |
| Gross Profit | 46.9M |
| Operating Expense | 272.3M |
| Operating I/L | -312.8M |
| Other Income/Expense | 20.0M |
| Interest Income | 4.3M |
| Pretax | -292.7M |
| Income Tax Expense | 1.2M |
| Net Income/Loss | -293.9M |
Novavax, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of vaccines for infectious diseases. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine in Phase III trials, NanoFlu, a seasonal quadrivalent influenza vaccine in Phase 3 clinical trial, and ResVax, a respiratory syncytial virus (RSV) vaccine candidate. Novavax also has collaboration with Takeda Pharmaceutical for the development and commercialization of NVX-CoV2373. The company generates revenue through the development, manufacturing, and commercialization of its vaccine candidates.
